论文部分内容阅读
[目的]研究培正散结通膈汤联合TP(紫杉醇+顺铂)方案治疗中晚期食管癌的疗效。[方法]将90例中晚期食管癌患者随机分为对照组和治疗组,治疗组使用培正散结通膈汤联合TP方案治疗,对照组使用单纯TP方案化疗,6个周期后比较两组疗效。[结果]治疗组病灶变化有效率(CR+PR)为48.9%,对照组为44.4%,两组比较无统计学差异(P>0.05);治疗组临床受益率(CR+PR+SD)为88.9%,对照组为66.7%,两者比较有统计学差异(P<0.05),表明治疗组可有效增加患者受益率。治疗组吞咽困难缓解率为88.9%,对照组为62.2%,两者比较有统计学差异(P<0.05),表明治疗组对缓解吞咽困难较对照组有更好的作用。治疗组在白细胞减少、血小板减少、骨髓抑制、恶心呕吐、便秘、神经感觉障碍等不良反应方面与对照组相比均有统计学差异(P<0.05),提示加用中药治疗组可有效减少化疗药物的不良反应。[结论]培正散结通膈汤联合TP方案治疗中晚期食管癌与对照组相比临床受益率显著提高、吞咽困难改善,不良反应减少。
[Objective] To study the curative effect of Peizheng Sanjie Tonglu Decoction combined with TP (paclitaxel + cisplatin) in the treatment of advanced esophageal cancer. [Methods] Ninety patients with advanced esophageal cancer were randomly divided into control group and treatment group. The treatment group was treated with Peizheng Sanjie Tonglu Decoction combined with TP regimen. The control group was treated with simple TP regimen. After 6 cycles, the two groups were compared Efficacy. [Results] The effective rate of CR + PR was 48.9% in the treatment group and 44.4% in the control group, there was no significant difference between the two groups (P> 0.05). The clinical benefit rate (CR + PR + SD) 88.9% in the control group and 66.7% in the control group (P <0.05), which shows that the treatment group can effectively increase the patients’ benefit rate. The treatment group dysphagia relief rate was 88.9%, 62.2% in the control group, the two were statistically significant (P <0.05), indicating that the treatment group to ease the dysphagia than the control group has a better effect. Compared with the control group, the treatment group had statistically significant differences (P <0.05) in leukopenia, thrombocytopenia, myelosuppression, nausea and vomiting, constipation, neurological sensation and other adverse reactions (P <0.05), suggesting that adding traditional Chinese medicine treatment group can effectively reduce the chemotherapy Adverse drug reactions. [Conclusion] Peizheng Sanjie Tonglu Decoction combined with TP regimen in treatment of advanced esophageal cancer patients compared with the control group, the clinical benefit rate was significantly improved, dysphagia improved, adverse reactions decreased.